Sugi Predict

Sugi Predict / Compounds / SCHEMBL20136946

SCHEMBL20136946

SCHEMBL20136946

CC(C)(C)OC(=O)COCCNC(=O)OCc1ccccc1

nearest known ligand 0.68

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 3/20 0.68
▸ LMNA P02545 1/20 0.68
▸ L3MBTL1 Q9Y468 2/20 0.54
▸ MAPT P10636 2/20 0.53
▸ IDO1 P14902 1/20 0.52
▸ HTT P42858 2/20 0.51
▸ SYK P43405 1/20 0.50
▸ KEAP1 Q14145 2/20 0.48
▸ NFE2L2 Q16236 2/20 0.48
▸ TGM2 P21980 1/20 0.46
▸ SLC1A3 P43003 1/20 0.44
▸ SLC1A1 P43005 1/20 0.44
▸ CASP1 P29466 1/20 0.43
▸ ABCB1 P08183 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4513964 0.98 SMN1; SMN2 (0.69) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL20526175 0.98 SMN1; SMN2 (0.69) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL903459 0.93 LMNA (0.58) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL25030131 0.92 LMNA (0.62) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL25030511 0.90 LMNA (0.59) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL25029156 0.90 LMNA (0.59) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL25030665 0.90 LMNA (0.58) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL1668653 0.89 SMN1; SMN2 (0.71) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL5533423 0.89 LMNA (0.56) SMN1; SMN2LMNAL3MBTL1MAPTIDO1
SCHEMBL20107353 0.88 LMNA (0.61) SMN1; SMN2LMNAL3MBTL1MAPTIDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2026-02-12 — — US disclosed
US-12521393-B2 Cytotoxicity targeting chimeras for CCR2-expressing cells GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2026-01-13 — — US disclosed
EP-4640280-A2 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2025-10-29 — — EP disclosed
EP-4384223-B1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE IP DEV LTD (GB) 2025-10-01 — — EP disclosed
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2025-05-01 — — US disclosed
US-20240325392-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-10-03 — — US disclosed
EP-4384224-A1 CYTOTOXICITY TARGETING CHIMERAS GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-06-19 — — EP disclosed
EP-4384223-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GlaxoSmithKline Intellectual Property Development Limited (GB) 2024-06-19 — — EP disclosed
CN-118103074-A Cytotoxic targeting chimeras for CCR2 expressing cells 葛兰素史克知识产权发展有限公司 2024-05-28 — — CN disclosed
WO-2023083895-A1 HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES AND METAL-FREE CLICK REACTIONS WITH THESE HYDROPHILIC AZADIBENZOCYCLOOCTYNE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2023-05-19 — — WO disclosed
WO-2023017484-A1 CYTOTOXICITY TARGETING CHIMERAS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 — — WO disclosed
WO-2023017483-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 — — WO disclosed
WO-2023017483-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2023-02-16 — — WO disclosed
CN-110267963-B MAGL inhibitors H.隆德贝克有限公司 2022-04-01 — — CN disclosed
EP-3541821-A1 MAGL INHIBITORS Abide Therapeutics, Inc. (US) 2019-09-25 — — EP disclosed
US-10093635-B2 MAGL inhibitors ABIDE THERAPEUTICS, INC. (US) 2018-10-09 — — US disclosed
WO-2018093947-A1 MAGL INHIBITORS ABIDE THERAPEUTICS, INC. (US) 2018-05-24 — — WO disclosed
US-20180134674-A1 MAGL INHIBITORS H. LUNDBECK A/S (DK) 2018-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180134674-A1 MAGL INHIBITORS MAG, MAGI3, MGLL SMN1; SMN2 1770/4885LMNA 3432/4885L3MBTL1 2479/4885
US-20260041686-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 SMN1; SMN2 1993/4885LMNA 4546/4885L3MBTL1 201/4885
US-20250136722-A1 CYTOTOXICITY TARGETING CHIMERAS HAVCR2, CD47, CYTH3 SMN1; SMN2 3486/4885LMNA 3657/4885L3MBTL1 463/4885
US-20240325392-A1 CYTOTOXICITY TARGETING CHIMERAS FOR CCR2-EXPRESSING CELLS CCR2, CCR1, CCRL2 SMN1; SMN2 3607/4885LMNA 4226/4885L3MBTL1 442/4885
US-10093635-B2 MAGL inhibitors MAG, MAGI3, MGLL SMN1; SMN2 1770/4885LMNA 3432/4885L3MBTL1 2479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.